Updated on 12 June 2015
ModiQuest has discovered the cellular mechanism of action of its therapeutic anti-citrullinated protein lead antibodies
Singapore: ModiQuest, a Dutch antibody drug development and diagnostics company focused on chronic inflammatory diseases, has discovered the cellular mechanism of action of its therapeutic anti-citrullinated protein lead antibodies (tACPA) for the treatment of rheumatoid arthritis (RA) and other diseases.
ModiQuest has discovered tACPAs using its proprietary antibody generation technology platforms ModiFuse (highly efficient hybridoma electrofusion technology), ModiSelect (B cell selection technology for low immunogenic or multiple antigen targets) and ModiPhage (proprietary phage display libraries). All three technology platforms are also used by ModiQuest's service business, ModiQuest Research, for custom antibody lead generation in third party service projects with a recent addition of an innovative platform for difficult antibody drug targets, ModiVacc.